Omnic Ocas (Tamsulosin Hydrochloride)

Tamsulosin Hydrochloride, the active ingredient in Omnic Ocas, is an alpha‑1 adrenergic receptor antagonist presented as a tablet for oral use. It treats benign prostatic hyperplasia related urinary symptoms in adult men. GNH USA supplies Omnic Ocas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Omnic Ocas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Omnic Ocas contains tamsulosin, an alpha‑blocker that relaxes smooth muscle in the urinary tract. It is indicated for: - Benign prostatic hyperplasia (BPH): improves urinary flow and reduces urgency and frequency. - Pre‑surgical preparation for transurethral resection of the prostate (TUR‑P): decreases intra‑operative bleeding. - Chronic prostatitis/chronic pelvic pain syndrome: may alleviate associated urinary discomfort. - Lower urinary tract symptoms (LUTS) secondary to BPH: eases nocturia and weak stream. - Urinary retention relief in men with BPH: facilitates bladder emptying. - Symptom management in men with an enlarged prostate: reduces the need for surgical intervention.

Tamsulosin may cause a range of adverse reactions. Common Side Effects: - Dizziness: especially after the first dose. - Headache: mild to moderate intensity. - Abnormal ejaculation: reduced volume or retrograde flow. - Nasal congestion: mild stuffiness. - Orthostatic hypotension: light‑headedness on standing.

Serious or Rare Side Effects: - Priapism: prolonged, painful erection. - Severe hypotension: fainting or shock. - Allergic reactions: rash, itching, swelling, or difficulty breathing. - Liver enzyme elevation: abnormal liver function tests. - Cardiac arrhythmias: irregular heartbeat. - Acute urinary retention: sudden inability to urinate.

When prescribing Omnic Ocas, clinicians should consider several safety aspects.

- Renal C‑        - Conduct "  "   - Monitor "); -   -  "  "   -  g  t  t. -   g  g " "  - " "   - " Final  t. -  t. -  t t. - ",